🧾 What This Document Is

This is an 8-K filing, which is a report companies use to announce major news to investors. In this case, Immunic is sharing official notice from Nasdaq that it has fixed a problem and is no longer at risk of being removed from the stock exchange.

🚨 The Core Announcement

Immunic received a letter from Nasdaq on March 27, 2026, confirming it has "regained compliance." This means the company successfully met a critical rule that its stock must trade above $1.00 per share.

👉 The Fix: The company's stock price stayed at or above $1.00 for 20 consecutive business days, satisfying the requirement on March 26, 2026. The issue is now officially closed.

🏢 What The Company Does

In simple terms, Immunic is a biotech company creating oral pills to treat brain and nerve diseases.

👉 Key Focus: Its main drug candidate is vidofludimus calcium (IMU-838), currently in Phase 3 trials for relapsing multiple sclerosis (MS). Top-line results from this major study are expected by the end of 2026. Earlier studies showed it helped in different types of MS.

⚖️ Big Picture: Why This Matters

👍 Strengths: Regaining compliance is a major relief. It removes the immediate threat of delisting, which would have made it much harder for investors to trade the stock and could have hurt the company's reputation and ability to raise money.

⚠️ Risks: The core business risk remains unchanged: the success of the company hinges on the future clinical trial results for its lead drug, IMU-838. The stock price fluctuation that led to the warning is a separate issue from the drug's development progress.

🔮 What's Next

With this administrative issue resolved, Immunic can now focus fully on its clinical pipeline. The next major milestone is the release of Phase 3 data for IMU-838 in MS by the end of 2026. The company is also developing earlier-stage drugs like IMU-856 and IMU-381.

🧠 The Analogy

Think of a student who was put on academic probation for getting grades below a certain threshold. They studied hard, raised their grades above the minimum for a full semester, and have now been taken off probation. They can focus on their main goal—graduating (like Immunic's drug approval)—without the immediate worry of being expelled.

📇 Key Contacts & People

• Jessica Breu

  • Title: Vice President Investor Relations and Communications
  • Phone: +49 89 2080 477 09
  • Email: [email protected]

• Paula Schwartz (US IR Contact, Rx Communications Group)

  • Phone: +1 917 633 7790
  • Email: [email protected]

• Caitlin Kasunich (US Media Contact, KCSA Strategic Communications)

  • Phone: +1 212 896 1241
  • Email: [email protected]

🧩 Final Takeaway

Immunic has cleared a major regulatory hurdle by getting its stock price back above $1.00, securing its listing on Nasdaq. This stabilizes the company's foundation, allowing it and investors to concentrate on the upcoming, crucial clinical trial results for its multiple sclerosis drug.